Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01785849
Registration number
NCT01785849
Ethics application status
Date submitted
5/02/2013
Date registered
7/02/2013
Date last updated
26/08/2019
Titles & IDs
Public title
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Query!
Secondary ID [1]
0
0
KAI-4169-006
Query!
Secondary ID [2]
0
0
20120229
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hyperparathyroidism, Secondary
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other endocrine disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Etelcalcetide
Treatment: Drugs - Placebo
Experimental: Etelcalcetide - Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
Placebo comparator: Placebo - Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
Treatment: Drugs: Etelcalcetide
Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
Treatment: Drugs: Placebo
Administered intravenously (IV) three times per week.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase
Query!
Assessment method [1]
0
0
Participants who did not have any scheduled assessments during the EAP were considered non-responders.
Query!
Timepoint [1]
0
0
Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Mean Predialysis Parathyroid Hormone = 300 pg/mL During the Efficacy Assessment Phase
Query!
Assessment method [1]
0
0
Participants who had no scheduled assessments during the EAP were considered non-responders.
Query!
Timepoint [1]
0
0
Baseline and the efficacy assessment phase (Week 20 to Week 27)
Query!
Secondary outcome [2]
0
0
Percent Change From Baseline in Predialysis PTH During the Efficacy Assessment Phase
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline and the Efficacy Assessment Phase (Week 20 to Week 27)
Query!
Secondary outcome [3]
0
0
Percent Change From Baseline in Predialysis Corrected Calcium During the Efficacy Assessment Phase
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline and the efficacy assessment phase (Week 20 to Week 27)
Query!
Secondary outcome [4]
0
0
Percent Change From Baseline in Predialysis Corrected Calcium Phosphorus Product During the Efficacy Assessment Phase
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline and the efficacy assessment phase (Week 20 to Week 27)
Query!
Secondary outcome [5]
0
0
Percent Change From Baseline in Predialysis Phosphorus During the Efficacy Assessment Phase
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline and the efficacy assessment phase (Week 20 to Week 27)
Query!
Eligibility
Key inclusion criteria
* Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
* Subject is 18 years of age or older.
* Subject must be receiving hemodialysis 3 times weekly for at least 3 months
* Subject agrees to not participate in another study of an investigational agent during the study.
* Other Inclusion Criteria may apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.
* Other investigational procedures while participating in this study are excluded.
* Anticipated or scheduled parathyroidectomy during the study period.
* Subject has received a parathyroidectomy within 3 months prior to dosing.
* Anticipated or scheduled kidney transplant during the study period.
* Subject has known sensitivity to any of the products or components to be administered during dosing.
* Subject has participated in a prior clinical trial of AMG 416 (also referred to as KAI-4169).
* Subject has received cinacalcet within the 4 weeks prior to screening labs (treatment with cinacalcet is prohibited during the study).
* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
* Other Exclusion Criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/03/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
12/06/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
508
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Liverpool
Query!
Recruitment hospital [2]
0
0
Research Site - St Leonards
Query!
Recruitment hospital [3]
0
0
Research Site - Parkville
Query!
Recruitment hospital [4]
0
0
Research Site - Prahan
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
3004 - Prahan
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Mississippi
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nevada
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
South Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Virginia
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
West Virginia
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Graz
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Linz
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Wien
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Aalst
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Baudour
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Bruxelles
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Leuven
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Liège
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Ontario
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Quebec
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Hradec Kralove
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Praha 4 - Nusle
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha 6
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Slavkov u Brna
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Trinec
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Nantes Cedex 01
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Poitiers
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Reims Cedex
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Saint-Ouen
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Salouel Cedex 1
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Berlin
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Dresden
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Kiel
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Villingen-Schwenningen
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Baja
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Budapest
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Gyor
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Kaposvar
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Pecs
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Ashkelon
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Nahariya
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Tel Aviv
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Milano
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Napoli
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Pavia
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
San Fermo Della Battaglia (CO)
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Verona
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Bialystok
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Warszawa
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Wroclaw
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Zamosc
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Saint Petersburg
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Saint-Petersburg
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Cantabria
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Cataluña
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Madrid
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
Cambridge
Query!
Country [67]
0
0
United Kingdom
Query!
State/province [67]
0
0
Coventry
Query!
Country [68]
0
0
United Kingdom
Query!
State/province [68]
0
0
Glasgow
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
London
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Nottingham
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
Salford
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01785849
Query!
Trial related presentations / publications
Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456. Kroenke MA, Weeraratne DK, Deng H, Sloey B, Subramanian R, Wu B, Serenko M, Hock MB. Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments. J Immunol Methods. 2017 Jun;445:37-44. doi: 10.1016/j.jim.2017.03.005. Epub 2017 Mar 6. Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V. A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-2. Stollenwerk B, Iannazzo S, Cooper K, Belozeroff V. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. J Med Econ. 2017 Oct;20(10):1110-1115. doi: 10.1080/13696998.2017.1360309. Epub 2017 Aug 14. Chen P, Narayanan A, Wu B, Gisleskog PO, Gibbs JP, Chow AT, Melhem M. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. Clin Pharmacokinet. 2018 Jan;57(1):71-85. doi: 10.1007/s40262-017-0550-4. Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS One. 2019 Mar 15;14(3):e0213774. doi: 10.1371/journal.pone.0213774. eCollection 2019. Cunningham J, Block GA, Chertow GM, Cooper K, Evenepoel P, Iles J, Sun Y, Urena-Torres P, Bushinsky DA. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019 Apr 16;4(7):987-994. doi: 10.1016/j.ekir.2019.04.010. eCollection 2019 Jul. Wolf M, Block GA, Chertow GM, Cooper K, Fouqueray B, Moe SM, Sun Y, Tomlin H, Vervloet M, Oberbauer R. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin Kidney J. 2019 Apr 26;13(1):75-84. doi: 10.1093/ckj/sfz034. eCollection 2020 Feb. Hain D, Tomlin H, Gibson C. Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective. Nephrol Nurs J. 2019 May-Jun;46(3):315-290.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01785849
Download to PDF